Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

Abigail I Nash1 Janssen Scientific Affairs, LLC, Titusville, NJ 08560, USA, [email protected]

Ibrahim Turkoz2 Janssen Research and Development, LLC, Titusville, NJ 08560, USA

Adam J Savitz2 Janssen Research and Development, LLC, Titusville, NJ 08560, USA

Maju Mathews2 Janssen Research and Development, LLC, Titusville, NJ 08560, USA

Edward Kim1 Janssen Scientific Affairs, LLC, Titusville, NJ 08560, USA, [email protected]Correspondence[email protected]

Pages 731-737 | Published online: 22 Mar 2019

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

References

LiebermanJAPerkinsDBelgerAThe early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approachesBiol Psychiatry2001501188489711743943
PubMed Web of Science ®Google Scholar
MillierASchmidtUAngermeyerMCHumanistic burden in schizophrenia: a literature reviewJ Psychiatr Res201454859324795289
PubMed Web of Science ®Google Scholar
JinHMosweuIThe societal cost of schizophrenia: a systematic reviewPharmacoeconomics2017351254227557994
PubMed Web of Science ®Google Scholar
CloutierMAigbogunMSGuerinAThe economic burden of schizophrenia in the United States in 2013J Clin Psychiatry201677676477127135986
PubMed Web of Science ®Google Scholar
HsiaoCYLeeCTLuHLTsaiYFLiving with schizophrenia: health-related quality of life among primary family caregiversJ Clin Nurs20172623–245151515928881102
PubMed Web of Science ®Google Scholar
AwadAGVorugantiLNPThe burden of schizophrenia on caregivers: a reviewPharmacoeconomics200826214916218198934
PubMed Web of Science ®Google Scholar
AndreasenNCCarpenterWTKaneJMLasserRAMarderSRWeinbergerDRRemission in schizophrenia: proposed criteria and rationale for consensusAm J Psychiatry2005162344144915741458
PubMed Web of Science ®Google Scholar
AlaqeelBMargoleseHCRemission in schizophrenia: critical and systematic reviewHarv Rev Psychiatry201220628129723216066
PubMed Web of Science ®Google Scholar
DochertyJPBossieCALachauxBPatient-based and clinician-based support for the remission criteria in schizophreniaInt Clin Psychopharmacol2007221515517159460
PubMed Web of Science ®Google Scholar
LambertMKarowALeuchtSSchimmelmannBGNaberDRemission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years laterDialogues Clin Neurosci201012339340720954433
PubMedGoogle Scholar
BrissosSDiasVVBalanzá-MartinezVCaritaAIFigueiraMLSymptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performanceSchizophr Res20111292–313313621514793
PubMed Web of Science ®Google Scholar
OlivaresJMSermonJHemelsMSchreinerADefinitions and drivers of relapse in patients with schizophrenia: a systematic literature reviewAnn Gen Psychiatry20131213224148707
PubMed Web of Science ®Google Scholar
KaneJMTreatment strategies to prevent relapse and encourage remissionJ Clin Psychiatry200768Suppl 142730
PubMed Web of Science ®Google Scholar
PenningtonMMccronePThe cost of relapse in schizophreniaPharmacoeconomics201735992193628534254
PubMed Web of Science ®Google Scholar
LiebermanJAStroupTSMcevoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
PubMed Web of Science ®Google Scholar
CooperDMoisanJGrégoireJPAdherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophreniaJ Clin Psychiatry200768681882517592904
PubMed Web of Science ®Google Scholar
MoisanJGrégoireJPPatterns of discontinuation of atypical antipsychotics in the province of Québec: a retrospective prescription claims database analysisClin Ther201032Suppl 1S21S3120152549
PubMed Web of Science ®Google Scholar
BossieCAAlphsLDCorrellCULong-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designsInt Clin Psychopharmacol201530527228126049673
PubMed Web of Science ®Google Scholar
WeidenPJKimEBermakJTurkozIGopalSBerwaertsJDoes half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of paliperidoneJ Clin Psychiatry2017787e813e82028640988
PubMed Web of Science ®Google Scholar
MarcusSCZummoJPettitARStoddardJDoshiJAAntipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital dischargeJ Manag Care Spec Pharm201521975476826308223
PubMed Web of Science ®Google Scholar
INVEGA TRINZA (paliperidone palmitate) prescribing informationTitusville, NJJanssen Pharmaceutica, Inc2017
Google Scholar
BerwaertsJLiuYGopalSEfficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trialJAMA Psychiatry201572883083925820612
PubMed Web of Science ®Google Scholar
SavitzAJXuHGopalSEfficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority studyInt J Neuropsychopharmacol2016197pyw01826902950
PubMed Web of Science ®Google Scholar
SavitzAJXuHGopalSNuamahIHoughDMathewsMPaliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority studyInt Clin Psychopharmacol201732632933628806194
PubMed Web of Science ®Google Scholar
MarderSRDavisJMChouinardGThe effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trialsJ Clin Psychiatry199758125385469448657
PubMed Web of Science ®Google Scholar
LibermanRPKopelowiczAVenturaJGutkindDOperational criteria and factors related to recovery from schizophreniaInt Rev Psychiatry2002144256272
Web of Science ®Google Scholar
VelliganDIKernRSGoldJMCognitive rehabilitation for schizophrenia and the putative role of motivation and expectanciesSchizophr Bull200632347448516641424
PubMed Web of Science ®Google Scholar
TurolaMCComelliniGGaluppiANanniMGCarantoniEScapoliCSchizophrenia in real life: courses, symptoms and functioning in an Italian populationInt J Ment Health Syst2012612223046890
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date